Isaac Kobrin
Executive Chairman of the Board of Directors
Claimed by owner Novaremed
Former names:
Medication for Chronic Neuropathic Pain
Novaremed
www.businesswire.com
•
Jul 21, 2022
Novaremed Enters Into an Exclusive Option and License Agreement With NeuroFront for the Non-opioid Neuropathic Pain Treatment, NRD.E1, for Greater China and Singapore
www.businesswire.com
•
Jun 23, 2022
Novaremed Announces Publication of Phase 1 and Phase 2a Study Data With NRD.E1 Demonstrating the Potential of This Investigational Non-opioid Pain Treatment
www.startupticker.ch
•
Dec 29, 2021
Novaremed's lead molecule enters Phase2b trials
www.businesswire.com
•
Sep 7, 2021
Novaremed Expands its Pipeline of Non-opioid Treatment Candidates for Chronic Pain Indications Through Acquisition of Metys Pharmaceuticals
www.finsmes.com
•
Feb 4, 2021
Novaremed Secures US$50M - FinSMEs
www.businesswire.com
•
Dec 18, 2020
Novaremed Receives Fast Track Designation from the FDA for NRD135S.E1 for the Treatment of Painful Diabetic Peripheral Neuropathy
www.biospace.com
•
Sep 15, 2020
Novaremed Announces Closing of a New Financing, Publication of PCT Patent Application and Participation at IASP Virtual Conference on Pain & Expo BioSpace
www.businesswire.com
•
Jun 23, 2020
Novaremed Announces U.S. FDA Approval of IND Application to Initiate Phase 2 Clinical Study of NRD135S.E1 for the Treatment of Painful Diabetic Peripheral Neuropathy
www.businesswire.com
•
Sep 2, 2019
Novaremed Secures Additional Financing and Strengthens Leadership
www.businesswire.com
•
Jul 29, 2019
Novaremed Announces Management Changes
www.biospace.com
•
May 17, 2019
Novaremed Presents Top-Line Results from Phase 2a Diabetic Neuropathic Pain Study of NRD.E1 at NeuPSIG 2019 BioSpace
www.businesswire.com
•
Mar 5, 2019
Nicholas Draeger Named New CEO of Novaremed AG
www.startupticker.ch
•
Oct 29, 2018
Novaremed gets closer to ambition
www.businesswire.com
•
Aug 23, 2018
Novaremed announces that it has raised CHF 6 million to prepare for a Phase 2b clinical study in Diabetic Neuropathic Pain
www.openaccessgovernment.org
•
Aug 23, 2017
Novaramed - Novel medication for neuropathic pain
www.globes.co.il
•
Jan 22, 2009
Pain treatment co Novaremed joins Ashkelon incubator
About
Novaremed, a privately held clinical-stage biopharmaceutical company, is developing effective and safe treatment options for managing chronic pain as an alternative to opioids.
The company's lead product is NRD.E1, an orally active non-opioid small molecule with a novel mechanism of action, FDA Fast Track Designation, and IND-approval to proceed with a Phase 2b clinical trial for the treatment of painful diabetic peripheral neuropathy.
The earlier stage pipeline addressing chronic pain includes candidates MP-101 (Phase 2 stage), targeting prevention and treatment of chemotherapy-induced peripheral neuropathy; and MP-103 (preclinical stage).
Novaremed's clinical development portfolio aims to satisfy high medical patient needs and societal demands by alleviating the burden of pain associated with diabetes and cancer for patients and countering over-reliance on addictive treatments.
Novaremed Ltd (Israel) and Metys Pharmaceuticals AG (Switzerland) are fully owned subsidiaries of Novaremed AG, domiciled in Basel (Switzerland).
The company's lead product is NRD.E1, an orally active non-opioid small molecule with a novel mechanism of action, FDA Fast Track Designation, and IND-approval to proceed with a Phase 2b clinical trial for the treatment of painful diabetic peripheral neuropathy.
The earlier stage pipeline addressing chronic pain includes candidates MP-101 (Phase 2 stage), targeting prevention and treatment of chemotherapy-induced peripheral neuropathy; and MP-103 (preclinical stage).
Novaremed's clinical development portfolio aims to satisfy high medical patient needs and societal demands by alleviating the burden of pain associated with diabetes and cancer for patients and countering over-reliance on addictive treatments.
Novaremed Ltd (Israel) and Metys Pharmaceuticals AG (Switzerland) are fully owned subsidiaries of Novaremed AG, domiciled in Basel (Switzerland).
Employees
Product stage
Primary Sector
Life Sciences & HealthTech
Products
NRD.E1
Geographic markets
Switzerland, United States, Europe
News
(16)
www.businesswire.com
•
Jul 21, 2022
Novaremed Enters Into an Exclusive Option and License Agreement With NeuroFront for the Non-opioid Neuropathic Pain Treatment, NRD.E1, for Greater China and Singapore
www.businesswire.com
•
Jun 23, 2022
Novaremed Announces Publication of Phase 1 and Phase 2a Study Data With NRD.E1 Demonstrating the Potential of This Investigational Non-opioid Pain Treatment
www.startupticker.ch
•
Dec 29, 2021
Novaremed's lead molecule enters Phase2b trials
www.businesswire.com
•
Sep 7, 2021
Novaremed Expands its Pipeline of Non-opioid Treatment Candidates for Chronic Pain Indications Through Acquisition of Metys Pharmaceuticals
www.finsmes.com
•
Feb 4, 2021
Novaremed Secures US$50M - FinSMEs
www.businesswire.com
•
Dec 18, 2020
Novaremed Receives Fast Track Designation from the FDA for NRD135S.E1 for the Treatment of Painful Diabetic Peripheral Neuropathy
www.biospace.com
•
Sep 15, 2020
Novaremed Announces Closing of a New Financing, Publication of PCT Patent Application and Participation at IASP Virtual Conference on Pain & Expo BioSpace
www.businesswire.com
•
Jun 23, 2020
Novaremed Announces U.S. FDA Approval of IND Application to Initiate Phase 2 Clinical Study of NRD135S.E1 for the Treatment of Painful Diabetic Peripheral Neuropathy
www.businesswire.com
•
Sep 2, 2019
Novaremed Secures Additional Financing and Strengthens Leadership
www.businesswire.com
•
Jul 29, 2019
Novaremed Announces Management Changes
www.biospace.com
•
May 17, 2019
Novaremed Presents Top-Line Results from Phase 2a Diabetic Neuropathic Pain Study of NRD.E1 at NeuPSIG 2019 BioSpace
www.businesswire.com
•
Mar 5, 2019
Nicholas Draeger Named New CEO of Novaremed AG
www.startupticker.ch
•
Oct 29, 2018
Novaremed gets closer to ambition
www.businesswire.com
•
Aug 23, 2018
Novaremed announces that it has raised CHF 6 million to prepare for a Phase 2b clinical study in Diabetic Neuropathic Pain
www.openaccessgovernment.org
•
Aug 23, 2017
Novaramed - Novel medication for neuropathic pain
www.globes.co.il
•
Jan 22, 2009
Pain treatment co Novaremed joins Ashkelon incubator
The Team
(5)
EKM
Eliahu Kaplan, M.D.
Founder & CEO
MS
Michal Silverberg
Head Of Clinical Operations
MR
Maurizio Rainisio
Head of Biometry
LHM
Liat Hochman, M.Sc.
Head of Operations
Connect with
What is the reason for connecting?
Your company *
Your position *
Add invitation message
0/300
Sending invitation...
Company Lifecycle
Private Equity Funding
A Round
$4.5M
Apr 2018
1 Investors
$4.5M
A Round
$6M
Aug 2018
2 Investors
$6M
Undisclosed Round
$2.66M
Sep 2019
1 Investors
$2.66M
Undisclosed Round
$2.7M
Sep 2020
1 Investors
$2.7M
Undisclosed Round
$50M
Feb 2021
1 Investors
$50M
Non-Equity Funding
Grant
$1.3M
Nov 2008
$1.3M
Mergers and Acquisitions
M&A
Undisclosed
Sep 2021
Type
Acquisition
Acquired
Metys Pharmaceuticals
Undisclosed
Media gallery
(0)Locations
Israel
HaSivim Street 24, Petah Tikva, Israel
Offices Abroad
Teichgaesslein 9, 4058 Basel
Locations
Israel
HaSivim Street 24, Petah Tikva, Israel
Offices Abroad
Teichgaesslein 9, 4058 Basel
Unlock financial data
Finder is provided for free by the non-profit organization Start-Up Nation Central.
- Get unlimited search results
- Save to custom lists - Smartlists
- Get notified with news and updates
- Connect with people
And much more...
I already have access,